FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of January 2007
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
1 Holding(s) in Company dated 02 January 2007
2 Blocklisting Interim Review dated 05 Janaury 2007
3 Holding(s) in Company dated 16 January 2007
4 Holding(s) in Company dated 19 Janaury 2007
5 Total Voting Rights dated 22 January 2007
6 Holding(s) in Company dated 25 January 2007
7 JE paediatric trial started 25 January 2007
8 Holding(s) in Company dated 29 Janaury 2007
Enclosure 1
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 2 January 2007 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces that it received notification on
22 December 2006 that as from 19 December 2006 Barclays PLC no longer held a
notifiable interest in the share capital of Acambis.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown,
Company Secretary Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP,
Communications and Investor Relations
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed
in association with St Louis University, has also been used to develop
ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it
the most advanced investigational vaccine against the West Nile virus. Acambis
also has the only vaccine in development against Clostridium difficile bacteria,
a leading cause of hospital-acquired infections. Recognised internationally as
the leading producer of smallpox vaccines, Acambis is developing an
investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use
stockpiles of this investigational vaccine for the US Government and other
governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure 2
SCHEDULE 5
BLOCKLISTING SIX MONTHLY RETURN
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1996 Approved Share Option Scheme
3. Period of return: From 01 July 2006 to 31 December 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
361,929
5. Number of shares issued/allotted under scheme during period:
Nil
6. Balance under scheme not yet issued/allotted at end of period:
361,929
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1995 Savings-Related Share Option Scheme
3. Period of return: From 01 July 2006 to 31 December 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
73,035
5. Number of shares issued/allotted under scheme during period:
nil
6. Balance under scheme not yet issued/allotted at end of period:
73,035
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1999 Share Option Plan
3. Period of return: From 01 July 2006 to 31 December 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
513,143
5. Number of shares issued/allotted under scheme during period:
nil
6. Balance under scheme not yet issued/allotted at end of period:
513,143
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
1. Name of company
Acambis plc
2. Name of scheme
OraVax 1990 Stock Incentive Plan
3. Period of return: From 01 July 2006 to 31 December 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
143,706
5. Number of shares issued/allotted under scheme during period:
Nil
6. Balance under scheme not yet issued/allotted at end of period:
143,706
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
1. Name of company
Acambis plc
2. Name of scheme
OraVax 1995 Stock Incentive Plan
3. Period of return: From 01 July 2006 to 31 December 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
104,179
5. Number of shares issued/allotted under scheme during period:
Nil
6. Balance under scheme not yet issued/allotted at end of period:
104,179
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
Contact for queries: Elizabeth Brown
Address: Acambis plc, Peterhouse Technology Park, 100 Fulbourn Road, Cambridge
CB1 9PT
Name of person making return: Elizabeth Brown
Telephone: 01223 275300
Position of person making return: Company Secretary
Date of return: 5 January 2007
Enclosure 3
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
Barclays PLC
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
The legal entities holding these shares are as follows:
Barclays Global Investors Ltd 1,296,745 shares
Barclays Bank PLC 2,147,482 shares
Barclays Capital Securities Ltd 1,014,027 shares
Gerrard Ltd 5,215 shares
Barclays Life Assurance Co Ltd 125,101 shares
5. Number of shares / amount of stock acquired
Not disclosed
6. Percentage of issued class
Not disclosed
7. Number of shares / amount of stock disposed
N/A
8. Percentage of issued class
N/A
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
Not disclosed
11. Date company informed
15 January 2007
12. Total holding following this notification
4,588,570 shares
13. Total percentage holding of issued class following this notification
4.26%
14. Any additional information
N/A
15. Name of contact and telephone number for queries
Elizabeth Brown tel: 01223 275300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown, Company Secretary
Date of notification
16 January 2007
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Enclosure 4
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 19 January 2007 - Acambis plc
("Acambis") (LSE: ACM) announces that it received notification today that as
from 17 January 2007 Barclays PLC no longer held a notifiable interest in the
share capital of Acambis.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary
Lyndsay Wright, VP, Communications and Investor Relations
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed
in association with St Louis University, has also been used to develop
ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it
the most advanced investigational vaccine against the West Nile virus. Acambis
also has the only vaccine in development against Clostridium difficile bacteria,
a leading cause of hospital-acquired infections. Recognised internationally as
the leading producer of smallpox vaccines, Acambis is developing an
investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use
stockpiles of this investigational vaccine for the US Government and other
governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure 5
Voting rights and capital
Cambridge, UK and Cambridge, Massachusetts - 22 January 2007 - Acambis plc
("Acambis") (LSE: ACM), in conformity with the Financial Services Authority's
("FSA") Transparency Directive transitional provision 6, notifies that on 20
January 2007 Acambis' share capital consisted of 107,667,727 ordinary 10p
shares, each share having equal voting rights.
This figure may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their interest in,
or a change to their interest in, Acambis under the FSA's Disclosure and
Transparency Rules.
-ends-
Enquiries:
Acambis plc
Lyndsay Wright, VP, Communications and IR
Elizabeth Brown, Company Secretary
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed
in association with St Louis University, has also been used to develop
ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it
the most advanced investigational vaccine against the West Nile virus. Acambis
also has the only vaccine in development against Clostridium difficile bacteria,
a leading cause of hospital-acquired infections. Recognised internationally as
the leading producer of smallpox vaccines, Acambis is developing an
investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use
stockpiles of this investigational vaccine for the US Government and other
governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure 6
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 25 January 2007 - Acambis plc
("Acambis") (LSE: ACM) announces an interest in its shares by JPMorgan Fleming
Mercantile Investment Trust Plc (JPMFMIT).
On 24 January 2007, Acambis received notification that JPMFMIT increased its
interest in Acambis shares to 3.23% on 19 January 2007. The number of shares
purchased by JPMFMIT was 400,000. The total number of shares now held by JPMFMIT
is 3,476,005, which represents a 3.23% interest in Acambis' issued share
capital.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275
300
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed
in association with St Louis University, has also been used to develop
ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it
the most advanced investigational vaccine against the West Nile virus. Acambis
also has the only vaccine in development against Clostridium difficile bacteria,
a leading cause of hospital-acquired infections. Recognised internationally as
the leading producer of smallpox vaccines, Acambis is developing an
investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use
stockpiles of this investigational vaccine for the US Government and other
governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure 7
Acambis starts paediatric trial of its single-dose JE vaccine in India
Cambridge, UK and Cambridge, Massachusetts - 25 January 2007 - Acambis plc
("Acambis") (LSE: ACM) announces that it has commenced a paediatric clinical
trial in India of ChimeriVaxTM-JE, its investigational single-dose vaccine
against Japanese encephalitis (JE). JE is a virus transmitted to humans by
mosquitoes and is the leading cause of childhood encephalitis and viral
encephalitis in Asia. This is the first time ChimeriVax-JE will have been tested
in children, who are the primary target population for the vaccine in endemic
regions.
The trial is a multi-centre randomised, double-blind, controlled paediatric
study and will be conducted in healthy children and infants. The trial aims to
evaluate the safety and immunogenicity of one dose of ChimeriVax-JE compared to
two doses of locally produced inactivated mouse-brain JE vaccine. In addition,
concurrent vaccination of ChimeriVax-JE and measles vaccine will be investigated
in the target age group for immunisation, children aged nine months to two
years.
Acambis' Chief Executive Officer Gordon Cameron commented:
"To date, ChimeriVax-JE has already been tested in approximately 2,400 adult
volunteers and we are excited to begin our first paediatric trial in India, a
country with JE-endemic regions in great need of a safe, single-dose, affordable
vaccine to prevent this dreadful disease. We are committed to meeting this need
with ChimeriVax-JE and the start of this trial brings us one step closer to
achieving this important goal."
In endemic areas, infants and children are at the greatest risk from JE. In
2005, a JE-epidemic in northern India and Nepal in 2005 caused 1,344 deaths,
almost all of those in children under the age of 15.
Once approved, ChimeriVax-JE will be marketed and distributed in India and
neighbouring countries by Acambis' partner, Bharat Biotech International Limited
(Bharat Biotech). One of India's leading biotechnology companies, Bharat Biotech
will also be responsible for end-stage fill/finish processing of ChimeriVax-JE
at its facilities in India.
-ends-
Enquiries:
Acambis plc
Gordon Cameron, Chief Executive Officer
David Lawrence, Chief Financial Officer
Lyndsay Wright, VP, Communications and IR
Tel: +44 (0) 1223 275 300
Brunswick
Jon Coles / Justine McIlroy / Margherita Lupi
Tel: +44 (0) 20 7404 5959
Notes to editors:
About Japanese encephalitis
Japanese encephalitis is a virus transmitted to humans by mosquitoes and is the
leading cause of childhood encephalitis and viral encephalitis in Asia. Every
year, there are an estimated 30,000 to 50,000 cases of JE, approximately 25-30%
of which are fatal; a high proportion of survivors are left with serious
neurological impairment. An estimated three billion people live in JE-endemic
regions, which include Thailand, China, Japan, India and parts of Australia.
About ChimeriVax-JE
- ChimeriVax-JE is being developed to provide a safe, affordable,
single-dose JE vaccine for travellers and those living in JE-endemic
regions.
- It is a live, attenuated, injectable vaccine and was developed using
Acambis' proprietary ChimeriVaxTM technology, which was developed in
association with St Louis University.
- In November 2006, Acambis announced positive safety results from pivotal
Phase 3 trials of ChimeriVax-JE, as well as promising preliminary results
from the Phase 3 efficacy trials. Additional data from the Phase 3
ChimeriVax-JE efficacy trials are expected during the first quarter of 2007.
- In previous trials, subjects vaccinated with ChimeriVax-JE exhibited an
immune response with long-term memory and a rapid rise in protective
antibodies on exposure to the virus.
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology has also
been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical
testing, making it the most advanced investigational vaccine against the West
Nile virus. Acambis also has the only vaccine in development against Clostridium
difficile bacteria, a leading cause of hospital-acquired infections. Recognised
internationally as the leading producer of smallpox vaccines, Acambis is
developing an investigational smallpox vaccine, ACAM2000, and is manufacturing
emergency-use stockpiles of this investigational vaccine for the US Government
and other governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor' statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management' in
the Company's 2005 Annual Report and "Risk factors' in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure 8
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
F&C Asset Management plc
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
As above
5. Number of shares / amount of stock acquired
N/A
6. Percentage of issued class
N/A
7. Number of shares / amount of stock disposed
Unknown
8. Percentage of issued class
Unknown
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
25 January 2007
11. Date company informed
26 January 2007
12. Total holding following this notification
5,198,913 shares
13. Total percentage holding of issued class following this notification
4.83%
14. Any additional information
None
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0) 1223 275 300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown
Date of notification
29 January 2007
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 31 January 2007 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.